NCT01296659

Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma

Phase Ib Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Patients With Advanced Unresectable Soft Tissue Sarcoma

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: The University of Texas Health Science Center at San Antonio · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Ridaforolimus has been tested in almost 2 dozen studies; however, it has not previously been tested in combination with the standard of care chemotherapy for sarcoma as this study will. We will be looking to see if Ridaforolimus given with SOC chemo (AIM or TG) is well tolerated and to determine a Phase 2 dose.

Conditions

• Soft Tissue Sarcoma

Interventions

Type	Name	Description
DRUG	ridaforolimus	Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy

Timeline

• Start date: 2011-02-01
• Primary completion: 2011-08-01
• Completion: 2011-08-01
• First posted: 2011-02-15
• Last updated: 2012-07-12

Locations

1 site across 1 country: United States